Funda Meric-Bernstam, MD

Funda Meric-Bernstam, MD, spoke about the TROPION-PanTumor01 trial results and the TROP2 targeting nature of dato-DXd in patients with heavily pretreated, metastatic urothelial cancer.

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Over the past 20 years, the combinationof breast-conservationsurgery and radiationtherapy has become the most commontreatment for the majority of patientswith invasive and in situ breastmalignancies. Extensive data fromboth randomized trials[1-3] and largeclinical databases have shown that thisapproach is equal to mastectomy interms of survival and provides excellentquality of life and patient acceptance.Nevertheless 10% to 15% ofpatients treated with breast-conservationsurgery and radiation will have alocal recurrence within the ipsilateralbreast (IBTR) within 10 years.[4-8]This paper will review the biology,clinical management, and outcomeof patients with ipsilateral breastrecurrence.